TMCnet News
Paragonix Technologies Inc. Announces Extension of Product Portfolio with the Addition of SherpaPak™ Lung Transport SystemParagonix Technologies, Inc. today announced expansion of its existing product portfolio of organ preservation and transport devices with the addition of SherpaPak™ Lung Transport System1,2. The SherpaPak™ Lung Transport System combines optimal homogenous hypothermic cooling with dynamic equilibration of lung airway pressure and organ parameter monitoring during storage and transport of donor lungs to recipients for implantation. Based on the similar single-use, disposable product strategy of the Paragonix SherpaPak™ Cardiac and Kidney Transport System, SherpaPak™ Lung Transport System is a unique, easy-to-use transport device to ensure optimal donor lung preservation between organ recovery and transplantation. The SherpaPak™ Lung Transport System aims to prevent and limit organ injury that occurs during conventional ice storage due to excessively cold temperatures and barotrauma3, the latter of which results from pressure changes in the lung during transport. Only one out of every five lungs (20%) donated in the U.S. can be used for transplantation based on the current method of lung preservation and transportation.4 The Paragonix Team will be advised by pulmonary expert Dr. Steven Keller, MD, Ph.D., who specializes in lung transplantation and critical care medicine at Brigham and Women's Hospital and is on faculty at the Harvard-MIT (News - Alert) Biomedical Engineering Center, where his work is focused on artificial organ support technologies. Dr. Keller commented. "As a lung transplant pulmonologist and biomedical engineer, I believe that optimal preservation of the donor lung is extremely important for the long term outcome of lung transplant recipients. I believe that much of the morbidity associated with the peri-transplant clinical course can be directly attributed to sub-optimally preserved donor organs. A cost-effective and easy-to-use transport system to ensure best possible preservation of donor lungs is critically needed. To achieve this, it is paramount to address both temperature and pressure-related issues that can negatively impact donor lung quality during transport. I believe that a system aimed at improving lung transport will greatly enhance organ quality. " In addition to Dr. Keller, Paragonix's Sherpa Lung Team will be supported by Dr. Hari Mallidi, who is the Co-Director for Lung Transplant, ECMO and Lung assist devices within the Surgical Program in Heart and Lung Transplantation and Mechanical and Circulatory Support at the Brigham and Women's Hospital (Boston), a Harvard Medical School Teaching Hospital. Jeff Goldstein, President and Founding Member of The Lung Transplant Foundation commented, "Our mission at The Lung Transplant Foundation is to promote and advance research in order to improve long-term outcomes among lung transplant recipients and to educate and promote awareness about organ donation. As a lung transplant recipient, I believe current methods of transportation and preservation of an extremely precious donor lung must be improved. The lung transplant field is in critical need of easy-to-use and effective preservation devices for the transport of lungs between organ donation and implantation." Lisa Anderson, PhD, President and COO, for Paragonix commented, "We are looking forward to working with a world-class team, all of whom bring incredibly valuable clinical experience to the Sherpa™ Lung Advanced Technology Expert Team. We are excited to expand our Sherpa™ platform with SherpaPak™ Lung Transport System."
Previous Announcements Paragonix previously announced March 27, 2017 Presentation of the SherpaPak™ Organ Transport Systems and SherpaPerfusion™ Cardiac Transport System at the 37th Annual Meeting of the International Society for Heart and Lung Transplantation (San Diego, 5 - 8 April 2017). Paragonix previously announced February 7, 2017 an exclusive distribution agreement with MBA Medical to market Paragonix Technologies' SherpaPak™ Cardiac and Kidney Transport Systems, in the Southern United States. Paragonix previously announced January 9, 2017 a Presentation of the SherpaPak™ Organ Transport Systems during the ASTS 17th Annual State of the Art Winter Symposium January 26 to 29, 2017 in Miami, FL. Paragonix previously announced January 4, 2017 an exclusive supply agreement with Sanbor Medical for the Manufacture and Assembly of SherpaPak™ Organ Transport Systems.
About The Lung Transplant Foundation
About the Paragonix SherpaPak™ and SherpaPerfusion™ Cardiac Transport
System
About the Lung Transplantation Market
About Paragonix Technologies, Inc. 1 The SherpaPak™ Lung Transport System and the SherpaPak™ product line are protected by patents, both issued and pending. 2 The SherpaPak™ Lung Transport System is not approved for sale in the U.S. 3 Ann Thorac Surg. 2010 May; 89(5): 1555-1562. 4 Organ Procurement and Transplant Network, http://optn.transplant.hrsa.gov 5 J Thorac Dis. 2010 Jun; 2(2): 111-116. 6 Orphanet J Rare Dis. 2008; 3: 8. 7 http://www.who.int/respiratory/copd/burden/en/ 8 https://optn.transplant.hrsa.gov/data/view-data-reports/national-data/ 9 http://www.transplants.org/faq/how-much-does-transplant-cost 10 Milliman Research Report, "2014 US Organ and Tissue Transplant Cost Estimates and Discussion" View source version on businesswire.com: http://www.businesswire.com/news/home/20170808005154/en/ |